Yee-Ming Chan1, Margaret F Lippincott, James P Butler, Valerie F Sidhoum, Cindy X Li, Lacey Plummer, Stephanie B Seminara. 1. Harvard Reproductive Sciences Center and Reproductive Endocrine Unit, Department of Medicine (Y-M.C., M.F.L.,V.F.S., C.X.L., L.P., S.B.S.), Massachusetts General Hospital, Boston, Massachusetts 02114; Division of Endocrinology, Department of Medicine (Y-M.C.), Boston Children's Hospital, Boston, Massachusetts 02115; and Division of Sleep Medicine (J.P.B.), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115.
Abstract
CONTEXT: Idiopathic hypogonadotropic hypogonadism (IHH) results from defective synthesis, secretion, or action of GnRH. Kisspeptin is a potent stimulus for GnRH secretion. OBJECTIVE: We probed the functional capacity of the GnRH neuronal network in patients with IHH. PARTICIPANTS: Eleven subjects with congenital IHH (9 men and 2 women) and one male subject who underwent reversal of IHH were studied. Six of the twelve subjects had an identified genetic cause of their IHH: KAL1 (n = 1), FGFR1 (n = 3), PROKR2 (n = 1), GNRHR (n = 1). INTERVENTION: Subjects underwent q10 min blood sampling to measure GnRH-induced LH secretion at baseline and in response to intravenous boluses of kisspeptin (0.24 nmol/kg) and GnRH (75 ng/kg) both pre- and post-six days of treatment with exogenous GnRH (25 ng/kg sc every 2 h). RESULTS: All subjects with abiding IHH failed to demonstrate a GnRH-induced LH response to exogenous kisspeptin. In contrast, the subject who achieved reversal of his hypogonadotropism demonstrated a robust response to kisspeptin. CONCLUSIONS: The functional capacity of the GnRH neuronal network in IHH patients is impaired, as evidenced by their inability to respond to the same dose of kisspeptin that effects a robust GnRH-induced LH response in healthy men and luteal-phase women. This impairment is observed across a range of genotypes, suggesting that it reflects a fundamental property of GnRH neuronal networks that have not been properly engaged during pubertal development. In contrast, a patient who had experienced reversal of his hypogonadotropism responded to exogenous kisspeptin.
CONTEXT: Idiopathic hypogonadotropic hypogonadism (IHH) results from defective synthesis, secretion, or action of GnRH. Kisspeptin is a potent stimulus for GnRH secretion. OBJECTIVE: We probed the functional capacity of the GnRH neuronal network in patients with IHH. PARTICIPANTS: Eleven subjects with congenital IHH (9 men and 2 women) and one male subject who underwent reversal of IHH were studied. Six of the twelve subjects had an identified genetic cause of their IHH: KAL1 (n = 1), FGFR1 (n = 3), PROKR2 (n = 1), GNRHR (n = 1). INTERVENTION: Subjects underwent q10 min blood sampling to measure GnRH-induced LH secretion at baseline and in response to intravenous boluses of kisspeptin (0.24 nmol/kg) and GnRH (75 ng/kg) both pre- and post-six days of treatment with exogenous GnRH (25 ng/kg sc every 2 h). RESULTS: All subjects with abiding IHH failed to demonstrate a GnRH-induced LH response to exogenous kisspeptin. In contrast, the subject who achieved reversal of his hypogonadotropism demonstrated a robust response to kisspeptin. CONCLUSIONS: The functional capacity of the GnRH neuronal network in IHH patients is impaired, as evidenced by their inability to respond to the same dose of kisspeptin that effects a robust GnRH-induced LH response in healthy men and luteal-phase women. This impairment is observed across a range of genotypes, suggesting that it reflects a fundamental property of GnRH neuronal networks that have not been properly engaged during pubertal development. In contrast, a patient who had experienced reversal of his hypogonadotropism responded to exogenous kisspeptin.
Authors: Gerasimos P Sykiotis; Nelly Pitteloud; Stephanie B Seminara; Ursula B Kaiser; William F Crowley Journal: Sci Transl Med Date: 2010-05-19 Impact factor: 17.956
Authors: Valerie F Sidhoum; Yee-Ming Chan; Margaret F Lippincott; Ravikumar Balasubramanian; Richard Quinton; Lacey Plummer; Andrew Dwyer; Nelly Pitteloud; Frances J Hayes; Janet E Hall; Kathryn A Martin; Paul A Boepple; Stephanie B Seminara Journal: J Clin Endocrinol Metab Date: 2013-01-01 Impact factor: 5.958
Authors: Hong N Bui; Patrick M Sluss; Stuart Blincko; Dirk L Knol; Marinus A Blankenstein; Annemieke C Heijboer Journal: Steroids Date: 2012-11-02 Impact factor: 2.668
Authors: Channa N Jayasena; Gurjinder M K Nijher; Alexander N Comninos; Ali Abbara; Adam Januszewki; Meriel L Vaal; Labosshy Sriskandarajah; Kevin G Murphy; Zohreh Farzad; Mohammad A Ghatei; Stephen R Bloom; Waljit S Dhillo Journal: J Clin Endocrinol Metab Date: 2011-10-05 Impact factor: 5.958
Authors: Margaret F Lippincott; Silvia León; Yee-Ming Chan; Chrysanthi Fergani; Rajae Talbi; I Sadaf Farooqi; Christopher M Jones; Wiebke Arlt; Susan E Stewart; Trevor R Cole; Ei Terasawa; Janet E Hall; Natalie D Shaw; Victor M Navarro; Stephanie Beth Seminara Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Ulrich Boehm; Pierre-Marc Bouloux; Mehul T Dattani; Nicolas de Roux; Catherine Dodé; Leo Dunkel; Andrew A Dwyer; Paolo Giacobini; Jean-Pierre Hardelin; Anders Juul; Mohamad Maghnie; Nelly Pitteloud; Vincent Prevot; Taneli Raivio; Manuel Tena-Sempere; Richard Quinton; Jacques Young Journal: Nat Rev Endocrinol Date: 2015-07-21 Impact factor: 43.330
Authors: Madison T Ortega; John A McGrath; Lauren Carlson; Vanessa Flores Poccia; Gary Larson; Christian Douglas; Bob Z Sun; Shanshan Zhao; Breana Beery; Hubert W Vesper; Lumi Duke; Julianne C Botelho; Armando C Filie; Natalie D Shaw Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Michael N Lehman; Lique M Coolen; Robert A Steiner; Genevieve Neal-Perry; Luhong Wang; Suzanne M Moenter; Aleisha M Moore; Robert L Goodman; Shel Hwa-Yeo; Stephanie L Padilla; Alexander S Kauffman; James Garcia; Martin J Kelly; Jenny Clarkson; Sally Radovick; Andy V Babwah; Silvia Leon; Manuel Tena-Sempere; Alex Comninos; Stephanie Seminara; Waljit S Dhillo; Jon Levine; Ei Terasawa; Ariel Negron; Allan E Herbison Journal: J Neuroendocrinol Date: 2018-04-14 Impact factor: 3.870